AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01127555
Drug: 5-fluorouracil, leucovorin, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
Trial: NCT00004142
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
Trial: NCT00003136
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02088502
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02387125
Drug: Metronomic CPA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01007071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo
Trial: NCT01341301
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02273635
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg excipients coated tablets twice a day orally administered for 24 months
Trial: NCT02594098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Trial: NCT01591421
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
Trial: NCT00000558
Drug: angiotensin-converting enzyme inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00316095
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00330044
Drug: Premetrexed (Alimta)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316952
Drug: Long acting β-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All dosages of LA propranolol and SA metoprolol
Trial: NCT01316952
Drug: Other α1/β-adrenergic antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
Trial: NCT01316952
Drug: Short acting Non-selective β-blockers and short acting β1-Selective agents
RxNorm normalized name: NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
Trial: NCT00300482
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg, daily, 12 weeks
Trial: NCT00300482
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily, 12 weeks, see Arm Description for dosage information
Trial: NCT00300482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type
Trial: NCT00199004
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199004
Drug: Dexamethasone / Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199004
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00048815
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT00671372
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00570934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01287221
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02564861
Drug: DS-1971a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
Trial: NCT02564861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching DS-1971a suspension
Trial: NCT04334382
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
Trial: NCT03924518
Drug: Placebo（Normal saline）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Trial: NCT04575818
Drug: GLPG4059 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG4059 for oral administration
Trial: NCT04575818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension
Trial: NCT04575818
Drug: GLPG4059 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG4059 for oral administration
Trial: NCT01113489
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml b.i.d.
Trial: NCT00100295
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg capsule taken three times a day
Trial: NCT00974285
Drug: Fuzheng 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Trial: NCT00974285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Trial: NCT04218162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01556776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Trial: NCT01628367
Drug: Medications
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
Trial: NCT02743780
Drug: MGV354 ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743780
Drug: MGV354 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as placebo comparator
Trial: NCT06184841
Drug: HAIC combined with intravenous PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
Trial: NCT01342744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tab oral twice a day
Trial: NCT01460407
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01460407
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00902421
Drug: Antimuscarinics
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinics for 3 months
Trial: NCT00103519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00600041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical infusion manner like experimental arm
Trial: NCT00462735
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
Trial: NCT00525824
Drug: Rosuvastatin (Crestor)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg and 20 mg
Trial: NCT00525824
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg and 80 mg
Trial: NCT02242981
Drug: LY2623091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01182974
Drug: dypirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gr PO/PZ/PR/IM
Trial: NCT01457677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to RO4995819 oral once daily for 6 weeks
Trial: NCT01457677
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral once daily for 6 weeks
Trial: NCT01457677
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oral once daily for 6 weeks
Trial: NCT01457677
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral once daily for 6 weeks
Trial: NCT01771432
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
Trial: NCT00733057
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline as an add-on drug (200 mg/day)
Trial: NCT00733057
Drug: Placebo (200 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00138047
Drug: zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02772796
Drug: SENS-218
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT00536016
Drug: JSM6427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
Trial: NCT00045747
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02958202
Drug: BMN 044 IV 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02958202
Drug: BMN 044 IV 9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02958202
Drug: BMN 044 SC 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539018
Drug: sorafenib plus tegafur-uracil
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
Trial: NCT03274427
Drug: Arginine hydrochloride
RxNorm normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Trial: NCT06437626
Drug: Mexidol
RxNorm normalized name: Brexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/ml IV solution, 250 mg tablets
Trial: NCT06437626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV solution, Placebo tablets
Trial: NCT02191761
Drug: SM04755
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating Doses
Trial: NCT02691403
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04134130
Drug: Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector
RxNorm normalized name: Gonal F RFF Pen 900 UNT per 1.5 ML Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
Trial: NCT04472676
Drug: LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01615055
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 mg fluoxetine po qd for 6 months
Trial: NCT04472676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02581397
Drug: Transpulmin suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
Trial: NCT00474864
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03824405
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle liquid formulation
Trial: NCT00262678
Drug: EN3267
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04233658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x2 capsules / day
Trial: NCT04233658
Drug: Cynara Scolymus
RxNorm normalized name: Cynara scolymus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x2 capsules / day
Trial: NCT01820455
Drug: Soap baths, Lubricating Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soap and water baths with lubricating jelly to the nares, once daily for 5 days
Trial: NCT05393414
Drug: Opioid based protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
Trial: NCT01247363
Drug: LY2608204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00377559
Drug: Non pegylated liposomal doxorubicin and docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: max. 6 courses
Trial: NCT02581397
Drug: Transpulmin syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7,5ml every 4 hours, orally, for 03 or 07 days
Trial: NCT03552536
Drug: MK-8583
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of MK-8583 in capsule form
Trial: NCT01752790
Drug: Top-down
RxNorm normalized name: Kool-Down Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Trial: NCT00005574
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02337283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02245789
Drug: Propofol and remifentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
Trial: NCT03040635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of Risdiplam matching placebo will be administered on Day 1.
Trial: NCT01991223
Drug: Dex infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
Trial: NCT00361699
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00481325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
Trial: NCT00823745
Drug: [14C]-PF-00868554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, single dose
Trial: NCT04401345
Drug: Glycopyrrolate 0.2 MG/ML
RxNorm normalized name: glycopyrrolate 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
Trial: NCT04401345
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, the patients will receive 1 ml of 0.9% normal saline
Trial: NCT01369082
Drug: Maintenance Immunosuppressive Treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
Trial: NCT00970450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02163720
Drug: Yondelis®-Caelyx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of Yondelis®-Caelyx® administration
Trial: NCT02885857
Drug: Shenyan Kangfu Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
Trial: NCT01188148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00800319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume matched placebo; oral solution; single dose
Trial: NCT02257177
Drug: Inhaled TD139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI Galectin-3 inhibitor
Trial: NCT02257177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI placebo
Trial: NCT00334360
Drug: Bus and Dex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Trial: NCT04104685
Drug: 3% Minocycline Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT00715364
Drug: NTx™-265: rhCG, then rEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Trial: NCT00715364
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Trial: NCT01765426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline (PBS)
Trial: NCT01510184
Drug: Y-90-Zevalin
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-90-Zevalin administered by intravenous infusion.
Trial: NCT01510184
Drug: In-111 Zevalin
RxNorm normalized name: In-111 Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-111-Zevalin administered by intravenously.
Trial: NCT02223611
Drug: S1 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
Trial: NCT02836873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive) tablet to match the active comparator
Trial: NCT04580745
Drug: MORF-057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.
Trial: NCT04580745
Drug: Placebo for MORF-057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.
Trial: NCT00405548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no